Brensocatib monohydrate: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
Brensocatib monohydrate: clinical details
Prescribing considerations
- Confirm non-cystic fibrosis bronchiectasis and the licensed exacerbation history.
- Safety and efficacy are not established below 12 years.
- Data are limited or absent in immunodeficiency, immunocompromised states and people receiving immunomodulatory therapy.
- Avoid live attenuated vaccines during treatment.
- This product is subject to additional safety monitoring.
Contraindications and cautions
- Hypersensitivity to brensocatib or any excipient.
- Use caution with moderate to severe neutropenia, defined as an absolute neutrophil count below 1,000/mm³.
Monitoring
- Review clinical response and exacerbation burden.
- Ask about skin, scalp, gum and periodontal symptoms and signs of infection.
- Review the effectiveness of concurrent CYP3A4-substrate respiratory treatments.
- Report suspected adverse reactions through the Yellow Card Scheme.
Clinical pharmacology
Brensocatib is a competitive, reversible DPP1 inhibitor. It is rapidly absorbed, metabolised mainly through CYP3A and is a substrate of P-glycoprotein and BCRP. Food does not materially alter overall absorption.
Formulation and product differences
- The selected product is a grey, round film-coated tablet marked “25” and “BRE”.
- It is essentially sodium-free and supplied in moisture-protective blister packaging.
Brensocatib monohydrate preparations and strengths
Tablet
Route: Oral
Strengths: 25 mg
Brensocatib monohydrate interactions
Tell the prescriber or pharmacist about all medicines and planned vaccinations. Interaction studies were conducted only in adults.
Live attenuated vaccines
Concurrent use has not been evaluated and should be avoided during treatment.
CYP3A4-substrate inhaled corticosteroids
Brensocatib may reduce their concentrations and therapeutic effect; review inhaled treatment if effectiveness declines.
CYP3A4-substrate macrolide antibiotics
Their concentrations and therapeutic effect may be reduced; assess concurrent treatment if effectiveness declines.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.